Abstract
Early hematogenous spread of cancer cells must be regarded as major cause for the later development of metastatic disease in patients with completely resected solid tumors, which account for the majority of cancer-related deaths in industrialized nations. Because current procedures for tumor staging usually fail to detect such micrometastases, immunocytochemical assays with monoclonal antibodies directed against epithelial differentiation antigens have been designed for the detection of individual micrometastatic carcinoma cells in secondary organs. The recent development of monoclonal antibodies directed to epithelial differentiation proteins has opened a diagnostic window to detect such disseminated carcinoma cells. Methods for immunocytochemistry are described in detail in Chapter 2 by Brooks. Several studies have shown that bone marrow is an important, clinically relevant indicator organ for early disseminated cancer cells derived from various epithelial organs, including breast, lung, colon, rectum, prostate, kidney, ovary, esophagus, and pancreas (for review, see ref. 1). The use of various detection antibodies and marker antigens has contributed to an enormous heterogeneity in the methodology applied.
The critical methodological evaluation of these antibodies in respect to specificity and sensitivity revealed considerable discrepancies in their potential to build a solid basis for a reliable and reproducible assay. Most of the studies were performed with monoclonal antibodies either against cytokeratin (2-5), a major constituent of the cytoskeleton in epithelial cells, or against membrane-bound mucins, such as epithelial membrane antigen, human milk fat globule, and tumor-associated glycoprotein-12 (6-8).
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Pantel, K., Braun, S., Passlick, B., Schlimok, G. (1996) Minimal residual epithelial cancer: diagnostic approaches and prognostic relevance.Histochem. Cytochem. 30, 1–60.
Schlimok, G., Funke, I., Holzmann, B., et al. (1987) Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. Proc. Natl. Acad. Sci. USA 84, 8672–8676.
Cote, R.J., Rosen, P.P., Lesser, M.L., et al. (1991) Prediction of early relapse in patients with operable breast cancer by detection of occult bone m micrometastases. J. Clin. Oncol. 9,1749–1756.
Lindemann, F., Schlimok, G., Dirschedl, P., et al. (1992) Prognostic significance of micrometastatic tumor cells in bone marrow of colorectal cancer patients. Lancet 340, 685–689.
Pantel, K., Schlimok, G., Braun, S., et al. (1993) Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl. Cancer Inst. 85, 1419–1424.
Mathieu, M.C., Friedman, S., Bosq, J., et al. (1990) Immunohistochemical staining of bone marrow biopsies for detection of occult metastasis in breast cancer. Breast Cancer Res. Treat. 15,21–26.
Diel, I.J., Kaufmann, M., Costa, S.D., et al. (1996) Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J. Natl. Cancer Inst. 88, 1652–1664.
Harbeck, N., Untch, M., Pache, L., et al. (1994) Tumor cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up. Br. J. Cancer 69,566–571.
Taylor-Papadimitriou, J., Burchell, J., Moss, F., et al. (1985) Monoclonal anti-bodies to epithelial membrane antigen and human milk fat globule mucin define epitopes expressed on other molecules. Lancet 1, 458.
Delsol, G., Gatter, K.C., Stein, H., et al. (1984) Human lymphoid cells express epithelial membrane antigen. Lancet 2, 1124–1128.
Heyderman, E., Macartney, J.C. (1985) Epithelial membrane antigen and lymphoid cells. Lancet 1, 109.
Pantel, K., Schlimok, G., Angstwurm, M., et al. (1994) Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. J. Hematother. 3, 165–173.
Braun S. Müller M. Hepp F. et al. 1998 Re Micrometastatic breast cancer cells in bone marrow at primary surgery progstic value in comparison with dal status. J. Natl. Cancer Inst. 90 1099–1100
Funke, I., Schraut, W. (1997) Meta-analysis of studies on bone marrow micrometastases: An independent prognostic impact remains to be substantiated. J. Clin. Oncol. 16, 557–566.
Pantel, K., Izbicki, J.R., Passlick, B., et al. (1996) Frequency and prognostic significance of isolated tumor cells in bone marrow of patients with non-small cell lung cancer without overt metastases. Lancet 347 649–653.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Humana Press Inc.
About this protocol
Cite this protocol
Braun, S., Pantel, K. (2001). Immunocytochemical Detection and Characterization of Individual Micrometastatic Tumor Cells. In: Brooks, S.A., Schumacher, U. (eds) Metastasis Research Protocols. Methods in Molecular Medicine, vol 57. Humana Press. https://doi.org/10.1385/1-59259-136-1:67
Download citation
DOI: https://doi.org/10.1385/1-59259-136-1:67
Publisher Name: Humana Press
Print ISBN: 978-0-89603-610-9
Online ISBN: 978-1-59259-136-7
eBook Packages: Springer Protocols